SGLT2 Inhibitors in Diabetic Nephropathy: A Systematic Review of SGLT2 Inhibitors Benefits in Diabetic Nephropathy
Abstract
Abstract Background: Diabetic nephropathy (DN), which affects 25–40% of those with type 2 diabetes (T2DM), is the main cause of end-stage kidney disease (ESKD) and a significant microvascular effect of diabetes mellitus. The need for better treatments is highlighted by the fact that disease progression frequently continues even after improvements in glycemic management and renin-angiotensin system (RAS) inhibition. Since they provide advantages beyond glucose management, such as kidney protection, sodium-glucose cotransporter-2 (SGLT2) inhibitors have become an attractive therapy option. Objective: This systematic review aims to evaluate the therapeutic potential, safety, and efficacy of SGLT2 inhibitors in the treatment of DN, with a focus on the renoprotective effects they have on individuals with type 2 diabetes. Method: A thorough literature search was carried out up until April 10, 2025, using PubMed, Google Scholar, PubMed Central, and ScienceDirect in accordance with PRISMA 2020 standards. Cohort studies published in English within the previous five years, meta-analyses, and randomized controlled trials (RCTs) were all considered eligible studies. The Quality Assessment Tool for Observational Cohort Studies, the Cochrane Risk of Bias Tool for RCTs, and AMSTAR 2 for meta-analyses were used to evaluate the risk of bias. Result: The inclusion of 243,682 patients from eight high-quality studies (two meta-analyses, three RCTs, and three cohort studies) was noted. SGLT2…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 243,682 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.